Europe Cancer Biomarkers Market Recent innovation & upcoming trends
Europe
Cancer Biomarkers Market Analysis and Size
Data
Bridge Market Research analyses that the cancer biomarkers market which was USD 4.15 billion in 2022,
would rocket up to USD 9.56 billion by 2030, and is expected to undergo a CAGR
of 11.0% during the forecast period 2023 to 2030. In addition to the insights
on market scenarios such as market value, growth rate, segmentation,
geographical coverage, and major players, the market reports curated by the
Data Bridge Market Research also include depth expert analysis, patient
epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Cancer Biomarkers Market Scope and Segmentation
|
REPORT
METRIC |
DETAILS |
|
Forecast
Period |
2023
to 2030 |
|
Base
Year |
2022 |
|
Historic
Years |
2021
(Customizable to 2015 - 2020) |
|
Quantitative
Units |
Revenue
in USD Billion, Volumes in Units, Pricing in USD |
|
Segments
Covered |
Product
(Consumables, Services, Software, Growth Hormone Therapy), Type (Safety
Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Protein Biomarkers,
Pharmacodynamics Biomarkers, Genetic Biomarkers), Profiling Technologies
(OMICS, Imaging Technology, Immunoassays, Cytogenetics and Bioinformatics),
Service (Sample Preparation, Assay Development, Biomarkers and Testing),
Application (Diagnostics Development, Drug Discovery and Development,
Personalized Medicine, Disease-Risk Assessment, Others), Disease (Prostate
Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and
Other Diseases), Indication (Cancer, Cardiovascular Disorders, Neurological
Disorders, Immunological Disorders, Others) |
|
Countries
Covered |
Germany,
France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain,
Turkey, Rest of Europe in Europe |
|
Market
Players Covered |
F.
Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.),
Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA
(Germany) , Bio-Rad Laboratories, Inc. (U.S.) , Enzo Biochem, Inc. (U.S),
Charles River Laboratories (U.S.), Eurofins Scientific (Luxembourg),
Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics
AG (Germany), General Electric (U.S.) |
|
Market
Opportunities |
|
Europe Cancer Biomarkers Market Dynamics
Drivers
- Rising R&D
activities
In November 2019, Hitachi and the Centre Léon Bérard cancer centre in
France promoted R&D aimed at improving the efficiency of cancer diagnosis
and treatment by establishing the Hitachi Lyon Lab. The research also includes
the identification of biomarkers in the context of resistance using genomic
data, which may allow for the prediction of responses and prognoses following
radiation treatment. As a result, the high cancer burden and increased R&D
activities are drive the market growth.
In addition, competitor analysis is performed very well in the large scale Europe Cancer Biomarkers Market report which takes into account vital aspects about the key players in the market such as strong and weak points of the competitors and analysis of their strategies with respect to product and market. Such details about competitive landscape plays very important role in deciding about the enrichments required in the product already in the market or the future product. This market report has been framed after thoroughly understanding business environment which best suits the requirements of the client. The top notch Europe Cancer Biomarkers Market business report provides estimations about the growth rate and the market value based on market dynamics and growth inducing factors.
- Rise in lung
cancer
Lung cancer is caused by the uncontrolled proliferation of abnormal cells
in one or both lungs. Although it can affect people who have never smoked,
smokers are at the greatest risk of developing lung cancer. The duration and
number of cigarettes smoked by the patient increase the risk of lung cancer.
Other risk factors include second-hand smoke, asbestos, certain metals, some
organic chemicals, radiation, air pollution, and diesel exhaust in the
workplace or in the environment. With the rise in cancer cases, millions of
people worldwide are becoming infected with COVID-19. Since the focus of
healthcare facilities has shifted to COVID-19, cancer patients' treatment and
cancer biomarker-related clinical trials have been paused for a period of time.
Opportunities
- Rising cancer
cases
According to Globocan 2020 estimates, there were 457,960 new cancer cases
in the United Kingdom, with prostate, breast, lung, colon, and skin cancer
being the most common types of cancer detected. According to the same
estimates, Italy had 415,269 new cancer cases and approximately 174,759 deaths.
As a result of the rising number of cancer cases, the cancer biomarkers market
in Europe is expected to grow significantly during the forecast period.
Restraints/Challenges
- High treatment
costs
The obstacles such as high investment requirements, high treatment costs,
and expensive capital expenditure on equipment are expected to stymie market
expansion, as are technical challenges with sample collection and a lack of
suitable reimbursement.
Access Full Report:-
https://www.databridgemarketresearch.com/reports/europe-cancer-biomarkers-market
With an international Europe Cancer Biomarkers Market research report, best market opportunities are brought into focus along
with the well-organized information to bring about growth in the market.
Industry outlook, critical success factors, industry dynamics, market
definition, drivers and restraints, market segmentation, value chain analysis,
key developments, application and technology outlook, regional or country level
analysis and competitive landscape are the key elements covered in the this
report. The credible Europe Cancer
Biomarkers Market report contains historic data along
with future forecast and detailed analysis for the market on a global and
regional level.
Request
Access for Sample Report:-
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-cancer-biomarkers-market
Table of Content:
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Europe Cancer
Biomarkers Market Landscape
Part 04: Europe Cancer
Biomarkers Market Sizing
Part 05: Europe Cancer
Biomarkers Market Segmentation By Product
Part 06: Five Forces
Analysis
Part 07: Customer Landscape
Part 08: Geographic
Landscape
Part 09: Decision Framework
Part 10: Drivers and
Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis
Get TOC of
the Report:-
https://www.databridgemarketresearch.com/toc/?dbmr=europe-cancer-biomarkers-market
About Us:
Data Bridge Market Research set forth itself as
an unconventional and neoteric Market research and consulting firm with
unparalleled level of resilience and integrated approaches. We are determined
to unearth the best Market opportunities and foster efficient information for
your business to thrive in the Market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgeMarketresearch.com
Browse
Related Reports@
·
Global Green Coatings Market
·
France Flow Cytometry Market
·
Europe Microplate Reader Market

Comments
Post a Comment